Hematologic Malignancy Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following hematologic malignancy clinical trials:

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Treatment agent: Pirtobrutinib (LOXO), venetoclax, Rituxamab
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund //Teresa.Lund@stjoe.org// (707) 521-3803
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04965493?term=NCT04965493&draw=2&rank=1
Sponsor: Loxo